openPR Logo
Press release

Acute Lymphoblastic Leukemia Market: Overview, Opportunities, In-Depth Analysis and Forecasts Upto 2025

07-27-2017 02:53 PM CET | Health & Medicine

Press release from: TMR - Research Reports

Acute Lymphoblastic Leukemia Market: Overview,

Acute lymphoblastic leukemia (ALL) is a cancer of white blood cells called as lymphocytes in bone marrow. It is a malignant disease in which early precursor lymphoid cells proliferate and replace the normal hematopoietic cells of bone marrow. ALL is the most common type of cancer in children. There is overproduction of lymphoblasts in the bone marrow when a person suffers from ALL that continuously multiply, damaging the bone marrow by preventing the production of normal cells such as red blood cells (RBC) and platelets. Increase in number of lymphoblast in the blood results in the decline of healthy RBCs, white blood cells, and platelets. This leads to anemia, bleeding, and infection. The cancer can spread to the spinal cord and the brain.

Obtain the Comprehensive Overview of Acute Lymphoblastic Leukemia (ALL) Market: http://www.transparencymarketresearch.com/acute-lymphoblastic-leukemia-market.html

There are several types of acute lymphoblastic leukemia. B-cell ALL, T-cell ALL, and Philadelphia chromosome-positive ALL (Ph+ ALL) are the three primary types of acute lymphoblastic leukemia. The most common type is the B-cell ALL. Philadelphia chromosome-positive ALL accounts for one third of all adult ALL, but is extremely rare in children. Treatment for Ph+ ALL patients involves precise drugs that target the gene product of Philadelphia chromosome.

Acute lymphoblastic leukemia can be characterized into childhood acute lymphoblastic leukemia and adult acute lymphoblastic leukemia. Major signs and symptoms related with acute lymphoblastic leukemia are anemia, paleness, fever, loss of appetite, pain in joints, bruising, weakness and fatigue, and lymph nodes enlargement. Factors such as increase in incidence of acute lymphoblastic leukemia among children and continuous innovation of therapies by key players are likely to drive the growth of this market in the near future. In addition, major factors driving the growth of the acute lymphoblastic leukemia market are rise in incidence and prevalence of ALL, increase in investment in research and development, and rise in health care expenditure. Launch of new products, agreements and collaborations, product pipelines, clinical trials, and acquisitions and mergers are some of the significant strategies adopted by key market players, which are projected to fuel the market growth for acute lymphoblastic leukemia. However, high costs of therapies and adverse events as a result of therapies are factors that impede the growth of the market.

The global acute lymphoblastic leukemia market has been segmented based on treatment type, drug class, end-user, and region. Based on treatment type, the acute lymphoblastic leukemia market is segmented into chemotherapy, radiation therapy, immunotherapy, and bone marrow transplantation. Availability of a wide range of chemotherapeutics agents for treatment of cancer and upcoming innovative improvement in the field of chemotherapy are factors which are anticipated to boost the market growth of the chemotherapy segment during the forecast period. Based on drug class, the global market is segmented into antineoplastic agents, corticosteroids, tyrosine kinase inhibitors, colony stimulating factors, and others. The others segment includes antifungals and antimicrobials, which are recommended to take as soon as the disease is detected. On the basis of end-user, the market is segmented into hospitals, clinics, and others.

Geographically, the global acute lymphoblastic leukemia market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Cancer is one of the leading causes of death in developed nations. North America holds a significant share of the global acute lymphoblastic leukemia market due to high incidence of acute lymphoblastic leukemia patients owing to genetic factors. Environmental factors and exposure to high dose of radiation are further contributing toward high incidence of ALL patients in this region. Asia Pacific is a highly lucrative market for acute lymphoblastic leukemia owing to increase in incidence of cancer patients.

Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22886

Major players operating in the market are Biogen Idec, Inc., Bristol-Myers Squibb, Celgene Corporation, ERYTECH Pharma, F. Hoffmann-La Roche Ltd., Genzyme Corporation, GlaxoSmithKline Pharmaceuticals Limited, and Pfizer, Inc.

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Lymphoblastic Leukemia Market: Overview, Opportunities, In-Depth Analysis and Forecasts Upto 2025 here

News-ID: 645070 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Acute

Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but
Pipeline Review, H2 2017 of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
"Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- '
Acute Renal Failure (ARF) (Acute Kidney Injury) Market: Industry Size, Share, Gr …
Latest industry research report on: Acute Renal Failure (ARF) (Acute Kidney Injury) Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape. Request For Sample Report
Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H2
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230595 Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood.
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth